Questions
Ipamorelin: common questions, answered from the literature
Direct answers to what people ask about ipamorelin and the CJC-1295 stack, cited where a number is involved.
What does CJC-1295 and ipamorelin do?
Together they raise growth hormone through two complementary mechanisms: CJC-1295 is a long-acting GHRH analog and ipamorelin is a ghrelin-receptor GHRP, and the classes act synergistically [7]. CJC-1295 produces a sustained GH and IGF-1 elevation [11]; ipamorelin adds a clean, selective GH pulse [1]. The combination itself has never been tested in a trial.
How much CJC-1295 ipamorelin should I take?
No peer-reviewed human protocol exists for the combination, so no dose can be presented as correct. Community subcutaneous regimens are anecdotal and not derived from any controlled human trial of the two together [3]. The literature establishes single-agent pharmacology — ipamorelin's ~2-hour half-life [2] and CJC-1295's multi-day GH elevation [11] — but not a combined human dose.
Does CJC-1295 ipamorelin work?
Each component changes GH and IGF-1 in single-agent studies, so the pharmacology is real [11] [1]. But "works" as a proven human outcome from the combination has never been demonstrated — there is no controlled trial of the two peptides together for any endpoint, and ipamorelin's lone human efficacy trial failed [3]. The case rests on mechanism, not combination outcome data.
Where to inject CJC-1295 ipamorelin?
Subcutaneous injection is the dominant route in community use, and it is also the route used in rodent body-composition studies of ipamorelin [4]. This site does not provide injection technique or a human protocol; subcutaneous self-administration of ipamorelin has no published human safety or pharmacokinetic characterization [3]. The studied human route was intravenous [2].
Can you take CJC-1295 ipamorelin and sermorelin together?
Pharmacologically the classes combine — sermorelin and CJC-1295 are both GHRH analogs and ipamorelin is a GHRP, and GHRP+GHRH pairings act synergistically [7]. In practice, stacking ipamorelin with one long-acting GHRH analog (CJC-1295) is more common than adding a second, short-acting one (sermorelin). No controlled trial has tested any such multi-peptide combination for an outcome [3].
Can you take tesamorelin and ipamorelin together?
They are complementary classes — tesamorelin is a GHRH analog and ipamorelin is a GHRP — so a GHRH+GHRP pairing is mechanistically coherent [7]. But there is no clinical trial of tesamorelin combined with ipamorelin, and ipamorelin has no approved use [3]. Any combination claim here is mechanistic inference, not demonstrated outcome data.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective agonist of the ghrelin / GHS-R1a receptor that releases growth hormone. In its founding characterization it released GH potently in rats and swine yet did not raise ACTH or cortisol even at doses more than 200-fold above its GH threshold — defining it as the first selective GH secretagogue [1].
What does ipamorelin do for you?
In studies, ipamorelin triggers a pulse of growth hormone via the ghrelin receptor, selectively — without raising cortisol or prolactin [1]. In rats it dose-dependently increased bone-growth rate [4]; in a 2024 ferret study it reduced chemotherapy-associated weight loss by about 24% [5]. Human outcome data is absent — its only efficacy trial failed [3] — so claims about what it does "for you" outrun the evidence.
What is ipamorelin peptide?
Ipamorelin peptide is a five-amino-acid (pentapeptide) ghrelin-receptor agonist, CAS 170851-70-4, derived by Novo Nordisk from the earlier compound GHRP-1. Two non-natural residues (Aib and D-2-naphthylalanine) make it resist enzymatic breakdown, and its hallmark is selectivity for GH release over cortisol and prolactin [1].
What are the risks of ipamorelin?
The biggest documented risk is the unknown: there is no long-term human safety data and only one short, failed Phase 2 trial (n=114), which showed no ipamorelin-specific signal over 7 days but no benefit [3]. Mechanistic cautions include GH-driven insulin resistance, IGF-1-related proliferative concerns, and a class-level cardiac signal seen with a related GHS-R1a agonist in rats [6].
Does ipamorelin reduce belly fat?
No human trial supports an ipamorelin fat-loss claim. In a 2024 ferret study, ipamorelin (1–3 mg/kg) blunted chemotherapy-induced weight loss by about 24% — the opposite context from fat reduction [5]. Community reports of a gradual leaner look exist but are anecdotal and confounded by diet and training, not clinical evidence.
What are the downsides of ipamorelin?
The central downside is that the human evidence is thin and mostly negative: one failed Phase 2 trial and no long-term safety database [3]. Reported adverse effects in research-use communities include facial flushing, increased appetite, transient tingling, mild water retention, and injection-site irritation — all anecdotal. A class-level cardiac signal from a related agonist adds caution [6].
Why is ipamorelin being discontinued?
Ipamorelin was never an approved product to discontinue; clinical development stalled because its only Phase 2 trial — for postoperative ileus (NCT00672074) — missed its primary endpoint and no further trials followed [3]. Separately, in 2024 the FDA removed ipamorelin acetate from the interim 503A Category 2 bulk-substances list, tightening compounding-pharmacy access.
Does ipamorelin increase IGF-1?
Not always in the short term. Ipamorelin releases GH, which can raise hepatic IGF-1 over sustained protocols, but in a 15-day rat bone-growth study it increased bone growth with no measurable change in total IGF-1 [4]. The IGF-1 response appears context- and duration-dependent rather than guaranteed.
How does CJC-1295 ipamorelin work?
The two act on different receptors that cooperate. CJC-1295 is a long-acting GHRH analog driving sustained GH and IGF-1 elevation [11]; ipamorelin is a ghrelin-receptor (GHS-R1a) agonist adding a selective GH pulse [1]. GHRP+GHRH pairings are synergistic and partially resistant to somatostatin, which is the documented rationale for combining the classes [7].
How to reconstitute CJC-1295 ipamorelin 5mg?
The research-supply literature treats this only as laboratory handling: lyophilized peptide is dissolved with bacteriostatic water and kept refrigerated, since peptides degrade with heat and freeze-thaw [2]. This site provides no volume, concentration, or administration instruction — there is no approved human ipamorelin preparation, alone or combined with CJC-1295.
How long does ipamorelin stay in your system?
Ipamorelin's terminal half-life in healthy human volunteers is approximately 2 hours, with clearance 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The GH pulse it triggers peaks around 40 minutes after dosing and is a single discrete event rather than a sustained elevation [2].
Does ipamorelin make you hungry?
It can. Ipamorelin acts on the ghrelin ("hunger hormone") receptor, and ghrelin-receptor agonists activate the brain's appetite centers [18]. In research-use communities, increased hunger after injection is an occasionally reported effect, described as milder than with GHRP-6 [anecdotal]. No human appetite data at research-use doses exists.
Will I gain weight on ipamorelin?
There is no human trial answer. In mice, ipamorelin stimulated adiposity and raised leptin independently of GH after two weeks [17], and its only human trial (in surgical patients) was not a body-weight study [3]. Community reports vary between a leaner look and water-retention puffiness, all anecdotal and confounded — not a basis for predicting weight change.
Does ipamorelin increase appetite?
Mechanistically yes — it is a ghrelin-receptor agonist, and central ghrelin/GHS-R1a activation induces feeding by activating brain appetite centers [18]. How strongly this translates to humans at research-use exposures is uncharacterized. In community reports the appetite bump is occasionally noted and described as milder than with less selective GHRPs, which is anecdotal.
What does ipamorelin peptide do?
Ipamorelin peptide selectively triggers a growth-hormone pulse by activating the ghrelin / GHS-R1a receptor, without meaningfully raising cortisol or prolactin [1]. Demonstrated animal effects include dose-dependent bone growth in rats [4] and reduced chemotherapy-associated weight loss in ferrets [5]. Human outcome evidence is absent — the one efficacy trial failed [3].
How long does it take for ipamorelin to work?
Pharmacologically, the GH response is fast: a single pulse peaking about 40 minutes after dosing, with a ~2-hour half-life [2]. Any perceived effects people describe — chiefly sleep changes — are reported within one to two weeks in community accounts, which are anecdotal and not from controlled trials. There is no validated human onset timeline.